The global clinical trials activity saw an increase of 0.1% in Q3 2021, when compared with the rolling average of the last four quarters (Q3 2020 to Q2 2021), according to GlobalData.
Of the overall activity, industry sponsored trials accounted for a 47.1% share in Q3 2021, marking a decrease of 1.6% in the total share when compared with the four-quarter average.
Go deeper with GlobalData
Non-industry sponsored trials accounted for a 52.9% share of all the clinical trials globally in Q3 2021, marking an increase of 1.6% in the overall share when compared with the four-quarter average.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top therapy areas for industry and non-industry sponsored clinical trials in Q3 2021
Oncology was the leading therapy area for industry sponsored clinical trials in Q3 2021, accounting for a 30.4% share of all trials.
This was followed by the following therapy areas: Infectious Disease with a 15.7% share, Central Nervous System with a 13.7% share, Gastrointestinal with a 6.9% share and Cardiovascular with a 6.6% share.
In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.5% share, followed by Infectious Disease with a 19.2% share, Central Nervous System with a 13.4% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.3% share.
| Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2021 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2021 | Activity |
| Oncology | 27.5% | 30.4% |  |
| Infectious Disease | 19.2% | 15.7% |  |
| Central Nervous System | 13.4% | 13.7% | |
| Gastrointestinal | 6.0% | 6.9% | |
| Cardiovascular | 7.3% | 6.6% | |
| Metabolic Disorders | 7.8% | 6.6% | |
| Immunology | 5.2% | 5.4% | |
| Respiratory | 6.0% | 5.1% | |
| Musculoskeletal Disorders | 3.9% | 4.1% | |
| Dermatology | 4.3% | 3.9% | |
| Hematological Disorders | 2.7% | 3.0% | |
| Ophthalmology | 3.0% | 2.7% | |
| Genito Urinary System And Sex Hormones | 2.6% | 2.6% | |
| Genetic Disorders | 1.7% | 1.9% | |
| Women’s Health | 1.9% | 1.9% | |
| Ear Nose Throat Disorders | 1.2% | 1.3% | |
| Male Health | 0.8% | 0.8% | |
| Hormonal Disorders | 0.5% | 0.6% | |
| Mouth and Dental Disorders | 0.6% | 0.6% | |
| Non Malignant Disorders | 0.2% | 0.5% | |
| Nutritional Disorders | 0.4% | 0.2% | |
Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q3 2021, accounting for a 25.2% share of all trials.
This was followed by the following therapy areas: Oncology with a 24.0% share, Infectious Disease with a 13.1% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.6% share.
In the last four quarters, Oncology System held a lead over others for non-industry sponsored clinical trials with an average share of 23.8%, followed by Central Nervous System with a 22.8% share, Infectious Disease with a 17.8% share, Cardiovascular with a 9.1% share, and Gastrointestinal with a 6.5% share.
| Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q3 2021 | |||
|---|---|---|---|
| Therapy Area | 4-Quarter Avg. | Q3 2021 | Activity |
| Central Nervous System | 22.8% | 25.2% | |
| Oncology | 23.8% | 24.0% | |
| Infectious Disease | 17.8% | 13.1% | |
| Cardiovascular | 9.1% | 8.9% | |
| Gastrointestinal | 6.5% | 6.6% | |
| Metabolic Disorders | 5.0% | 5.5% | |
| Musculoskeletal Disorders | 5.0% | 5.2% | |
| Women’s Health | 4.1% | 4.1% | |
| Respiratory | 4.9% | 3.9% | |
| Dermatology | 2.7% | 3.0% | |
| Genito Urinary System And Sex Hormones | 2.9% | 3.0% | |
| Hematological Disorders | 2.7% | 2.8% | |
| Immunology | 3.4% | 2.7% | |
| Mouth and Dental Disorders | 2.2% | 2.7% | |
| Ophthalmology | 1.8% | 1.8% | |
| Ear Nose Throat Disorders | 1.0% | 1.2% | |
| Hormonal Disorders | 0.8% | 1.0% | |
| Genetic Disorders | 0.6% | 0.8% | |
| Male Health | 0.5% | 0.5% | |
| Nutritional Disorders | 0.7% | 0.5% | |
| Non Malignant Disorders | 0.4% | 0.2% | |
Top regions in industry and non-industry sponsored clinical trials activity in Q3 2021
Asia-Pacific held the top position for industry sponsored clinical trials activity in Q3 2021 with a 47.1% share, compared to 52.8% in the last four quarters.
North America stood at second place with a 34.0% share in Q3 2021, over 33.4% in the last four quarters, followed by Europe with a 32.2% share in Q3 2021, as against 29.1% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held an 84.3% share in industry sponsored clinical trials in Q3 2021 when compared with 82.7% of average recorded in the last four quarters. Multinational trials accounted for a 15.7% share in Q3 2021, as against the four-quarter average of 17.4%.
Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q3 2021 with a 53.6% share, over 51.4% in the last four quarters.
North America held the second position with a 20.1% share in Q3 2021, over 17.2% in the last four quarters, followed by Middle East and Africa with a 14.6% share in Q3 2021, as against 15.1% in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Single country studies held a 99.0% share for non-industry sponsored clinical trials in Q3 2021, compared to 98.7% in the last four quarters. Multinational trials accounted for a 1.0% share in Q3 2021, as against 1.3% in the last four quarters.
Industry and non-industry sponsored clinical trials by Phase in Q3 2021
Phase II trials outnumbered all other studies with a 39.3% share for industry sponsored trials in Q3 2021, compared to 35.6% average in the last four quarters.
The share of Phase I trials stood at 32.2% in Q3 2021, as against the four-quarter average of 35.1%. Phase III trials held a 17.3% share in Q3 2021, registering an increase of 0.6% over the last four quarters average, followed by Phase IV trials with an 11.2% share in Q3 2021, as against the four-quarter average of 12.6%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Phase II trials outnumbered all other trials with a 42.1% share for non-industry sponsored clinical trials in Q3 2021, compared to 44.4% in the last four quarters.
Phase IV trials stood at second place with a 22.1% share in Q3 2021, compared to 21.4% in the last four quarters. Phase III trials held a 19.2% share in Q3 2021, as against 18.3% in the last four quarters, followed by Phase I trials with a 16.6% share in Q3 2021 over 15.8% average recorded in the last four quarters.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
